OBJECTIVE: To systematically evaluate the efficacy and safety of magnesium isoglycyrrhizinate in the prevention of liver injury induced by chemotherapy.METHODS: CNKI

Wanfang database

VIP database

PubMed and the Coehrane library were retrieved to collect the randomized controlled trial（ RCT） of magnesium isoglycyrrhizinate in the prevention of liver injury induced by chemotherapy [the study group was given magnesium isoglycyrrhizinate injection

while the control group received other kinds of hepatoprotective drugs（ tiopronin

glutathione

diammonium glycyrrhizinate）; outcome indicators included the incidence of abnormal liver function

the levels of alanine aminotransferase（ ALT）

alkaline phosphatase（ ALP）

total bilirubin（ TBIL） and the incidence of adverse drug reactions].Cochrane Bias Risk Assessment Scale was used to evaluate the methodological quality of the included literature.RevMan 5.3 software was used for Meta-analysis.RESULTS: Totally 13 literature were extracted

including 1 418 patients.Meta-analysis showed that the incidence of abnormal liver function（ RR = 0.44

95% CI =0.33-0.59

P<0.000 01）

levels of ALT（ MD =-10.81

95% CI =-14.20--7.43

P < 0.000 01）

ALP（ MD =-15.56

95%CI =-20.78--10.34

P<0.000 01） and TBIL（ MD =-4.00

95%CI =-5.24--2.77

P <0.000 01） in the study group were significantly lower than those in the control group

and the differences were statistically significant.There was no significant difference in the incidence of adverse drug reactions between the study group and the control group（ RR = 0.72

95% CI = 0.37-1.38

P = 0.32）.CONCLUSIONS: The effects of prophylactic use of magnesium isoglycyrrhizinate in reducing the incidence of abnormal liver function induced by chemotherapy and improving levels of ALT

ALP

TBIL is better than that of other liver protective drugs

and does not increase the incidence of adverse drug reactions

which has clinical application value.